Nilafustin (Anidulafungin)

Anidulafungin, the active ingredient in Nilafustin, is an echinocandin presented as a sterile powder for intravenous infusion. It is used to treat invasive candidiasis and other serious Candida infections in adult patients, and is administered by healthcare professionals in hospital settings.

GNH USA supplies Nilafustin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, ensuring quality, regulatory compliance and cold‑chain logistics for global delivery.

Nilafustin (anidulafungin) is indicated for several serious Candida infections.

Invasive candidiasis: provides effective treatment of bloodstream and deep‑tissue Candida infections in adults. Candida esophagitis: clears fungal infection of the esophagus and relieves associated symptoms. Candida peritonitis: resolves intra‑abdominal Candida infection in patients with peritoneal contamination. Candida bloodstream infections: eradicates fungemia caused by susceptible Candida species.

Anidulafungin may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Infusion‑related reactions (flushing, rigors, or chest discomfort) - Fever or chills during administration - Nausea or mild gastrointestinal upset - Elevated liver enzymes (ALT, AST)

Serious or Rare Side Effects: - Severe hepatic injury or jaundice - Anaphylaxis or severe hypersensitivity reactions - Severe hypotension or cardiovascular collapse - Stevens‑Johnson syndrome or other severe skin reactions

Before initiating Nilafustin, clinicians should consider several safety measures.

Renal function: monitor renal parameters in patients with pre‑existing kidney disease. Hepatic function: assess liver enzymes before and during therapy. Drug interactions: review concomitant medications for potential interactions. Pregnancy and lactation: use only if the potential benefit justifies the risk to the fetus or infant. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Anidulafungin can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP450 inducers (e.g., rifampin): may markedly reduce anidulafungin exposure. - Concurrent use with other echinocandins: increased risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase plasma levels of anidulafungin. - Immunosuppressants (e.g., tacrolimus, cyclosporine): may require dose adjustment and therapeutic drug monitoring. - Statins (e.g., simvastatin): monitor for signs of myopathy or elevated creatine kinase.